Trials / Completed
CompletedNCT01150058
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
Preclinical Evaluation of Novel CD33-Targeting Therapeutics for Treatment of Acute Myeloid Leukemia (AML)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying cell samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer PURPOSE: This research study is studying drug biomarkers in cell samples from patients with acute myeloid leukemia.
Detailed description
OBJECTIVES: * To determine, in vitro, the cytotoxic activity of novel CD33-targeting immunoconjugate agents in cell samples from patients with acute myeloid leukemia (AML). * To define the characteristics of AML cells responding to or resisting these agents. OUTLINE: Cell samples are thawed and used for in vitro studies to determine the cytotoxic activity of novel CD33-targeting immunoconjugate agents, including gemtuzumab ozogamicin, for genotyping characterization by flow cytometry-based assays and/or western blot, and colony-forming cell assays.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | western blotting | |
| OTHER | flow cytometry | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2010-06-24
- Last updated
- 2015-05-12
Source: ClinicalTrials.gov record NCT01150058. Inclusion in this directory is not an endorsement.